FM11 476
e59
Re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar,
Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol. 2017;71:606–17 http://dx.doi.org/10.1016/j.eururo.2017.06.006L. Marconi, S. MacLennan, T.B.L. Lam, S.E. Canfield, Y. Yuan, M.I. Omar, J. N’Dow, R. Sylvester
e61
Reply to Lorenzo Marconi, Steven MacLennan, Thomas B.L. Lam, et al’s Letter to the Editor re: Maria Carmen Mir, Ithaar Derweesh, Francesco Porpiglia, Homayoun Zargar, Alexandre Mottrie, Riccardo Autorino. Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. Eur Urol 2017;71:606–17 http://dx.doi.org/10.1016/j.eururo.2017.06.005I.H. Derweesh, M.C. Mir, R. Autorino
e63
Re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle- invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952–60 Methodological Issues to Avoid Misinterpretation http://dx.doi.org/10.1016/j.eururo.2017.06.008S. Safiri, E. Ayubi
e64
Reply to Saeid Safiri and Erfan Ayubi’s Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder- preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952–60. Methodological Issues to Avoid Misinterpretation http://dx.doi.org/10.1016/j.eururo.2017.06.007N.J. Giacalone, A. Niemierko, W.U. Shipley, J.A. Efstathiou
e66
Re: Declan G. Murphy, Christopher J. Sweeney, Bertrand Tombal. “Gotta Catch ‘em All” or Do We? Pokemet Approach to Metastatic Prostate Cancer. Eur Urol 2017;72:1–3. http://dx.doi.org/10.1016/j.eururo.2017.06.011A.C. Tree, S. Siva, P. Ost
e68
Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838–40 Clinical Utility of Trial-estimated Prognostic Models http://dx.doi.org/10.1016/j.eururo.2017.04.030T. Mirtti, T. Aittokallio
e70
Reply to Tuomas Mirtti and Tero Aittokallio’s Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-
resistant Prostate Cancer? Eur Urol. 2017;71:838–40. Clinical Utility of Trial- estimated Prognostic Models http://dx.doi.org/10.1016/j.eururo.2017.04.031F. Seyednasrollah, M. Mahmoudian, L. Rautakorpi, O. Hirvonen, T. Laitinen, S. Jyrkkiö, L.L. Elo
e72
Re: James J. Hsieh, David Chen, Patricia I. Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14 http://dx.doi.org/10.1016/j.eururo.2017.01.012Y. Lei, S. Yildiz, M. Chen
e74
Reply to Ye Lei, Serdar Yildiz, and Minfeng Chen’s Letter to the Editor re: James J. Hsieh, David Chen, Patricia Wang, et al. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Eur Urol 2017;71:405–14 http://dx.doi.org/10.1016/j.eururo.2017.01.013J.J. Hsieh, M. Marker, D. Chen
e76
Congress Calendare u r o p e a n u r o l o g y , vo l . 7 2 , n o . 3 , S e p t emb e r 2 0 1 7
Letters to the Editor
published online